Nycomed's Teslascan MRI agent is cleared

Article

The Food and Drug Administration has approved a new MRI contrast agent developed by Nycomed Amersham for liver studies. The Buckinghamshire, U.K., company announced on Dec. 1 that Teslascan received the FDA's go-ahead. In addition to Nycomed Amersham's

The Food and Drug Administration has approved a new MRI contrast agent developed by Nycomed Amersham for liver studies. The Buckinghamshire, U.K., company announced on Dec. 1 that Teslascan received the FDA's go-ahead. In addition to Nycomed Amersham's marketing effort, Teslascan will be sold in the U.S. by Schering subsidiary Berlex Laboratories of Wayne, NJ. Berlex gained rights to Teslascan in 1992 in exchange for settling its claim that Nycomed's Omniscan MRI agent infringed on patents Schering holds for its Magnevist product (SCAN 8/26/92).

Berlex will market Teslascan under its own label and trade name, but the company has not yet determined what it will call the product, according to a Berlex spokesperson. Teslascan is not covered by Berlex's contrast media licensing agreement with Abbott Laboratories, which distributes Magnevist and x-ray contrast agent Ultravist

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.